Tsuyoshi Kaneko
Latest contributions
Future devices and techniques for structural heart disease
15 Feb 2026 – From PCR Tokyo Valves 2026
This session surveys the future landscape of structural heart disease treatment, addressing current limitations in transcatheter valve technologies and presenting emerging devices and techniques for aortic, mitral, and tricuspid valves. Attendees will gain insights into innovations poised to transform therapeutic options for structural heart disease.
Guidelines update
15 Feb 2026 – From PCR Tokyo Valves 2026
This session reviews the latest updates in the ESC/EACTS guidelines for structural heart disease, emphasizing their clinical implications and future trends. Participants will gain understanding of changes in aortic, mitral, and tricuspid valve recommendations, including new age cutoffs, asymptomatic disease management, and the evolving role of...
TAVI today and tomorrow: international trends and future direction
14 Feb 2026 – From PCR Tokyo Valves 2026
This session focuses on the evolving landscape of TAVI, emphasising lifetime management strategies with a focus on the first valve implanted. It provides a comprehensive discussion on representative patient profiles, current guidelines from various countries, and future outlooks, alongside recent long-term clinical results for the balloon-expandable...
Learn from the experts: lifetime management for Evolut first redo TAVI (TAV-in-TAV) and explant
14 Feb 2026 – From PCR Tokyo Valves 2026
This session offers an in-depth exploration of lifetime management strategies for patients undergoing Evolut first redo TAVI procedures, including TAV-in-TAV and explant techniques. It provides a comprehensive understanding of clinical decision-making algorithms, technical challenges, and key considerations for successful procedural planning and execution, supported by real-world...
Mitral and aortic transcatheter valve-in-valve intervention - LIVE case
14 Feb 2026 – From PCR Tokyo Valves 2026
Live case
An 83-year-old male with AF, CKD (stage 3A), preserved LV function, and a history of AVR (27 mm Magna Ease) and MVR (33 mm Magna) in 2014 presented with symptomatic stenosis of the mitral bioprosthesis. A Sapien 3 valve was implanted in the Magna mitral...
Late-breaking trials of PCR Tokyo Valves 2026
14 Feb 2026 – From PCR Tokyo Valves 2026
This session presents pivotal late-breaking trials from PCR Tokyo Valves 2026, offering one-year outcomes and real-world experiences in transcatheter valve therapies. Highlights include the AltaValve early feasibility study on atrial fixation TMVR, invasive registry insights on prosthesis-patient mismatch post-TAVR, and registry data on tricuspid and mitral...
Mastering techniques from basic to complex - Advanced TAVI
13 Feb 2026 – From PCR Tokyo Valves 2026
Explore advanced TAVI topics including valve selection for small annuli, optimization strategies for bicuspid aortic valve interventions, and techniques ensuring safety and efficacy in valve-in-valve procedures.
Transcatheter mitral valve replacement in practice
18 Nov 2025 – From PCR London Valves 2025
This session provides an in-depth overview of transcatheter mitral valve replacement (TMVR) in clinical practice, focusing on patient and anatomical suitability assessments including imaging parameters and risk factors for left ventricular outflow tract obstruction. It covers anatomical preparation techniques such as leaflet modification, prior clip removal,...
TAV in TAVI with coronary protection - LIVE Case
18 Nov 2025 – From PCR London Valves 2025
Watch a LIVE case followed by a recorded case, regarding a 78-year-old female, with a previous TAVI in 2014 (Sapien 3 26) and sarcoidosis, who presented with symptomatic TAVI stenosis. There was a mis-commissural alignment, with the neoskirt plane above the coronary plane. Under general anesthesia,...
Featured research - Mitral valve interventions: Physiology & device innovation
17 Nov 2025 – From PCR London Valves 2025
This session highlights groundbreaking research on mitral valve interventions featuring advanced transcatheter techniques. Topics include coronary physiology assessment with vFFR in severe mitral regurgitation, predictive versus actual outcomes in TMVR, innovative devices like Epygon and INNOVALVE, and novel approaches such as the ReNiva posterior leaflet replacement...
Mitral valve-in-valve: high-left ventricular outflow tract obstruction risk
16 Nov 2025 – From PCR London Valves 2025
This session focuses on the management of high-risk left ventricular outflow tract (LVOT) obstruction in mitral valve-in-valve procedures. It discusses innovative approaches such as the tip-to-base LAMPOON procedure to mitigate obstruction risk, techniques for cutting obstructive tissue, and combined strategies involving sentinel-protected submitral aneurysm closure and...
Imaging aortic valve
09 Feb 2025 – From PCR Tokyo Valves 2025
Explore cutting-edge imaging techniques to assess and guide the management of aortic valve disease in this comprehensive session. From preprocedural assessment with TEE to advanced CT and MRI strategies, learn how to evaluate and treat patients with low-flow low-gradient aortic stenosis, aortic regurgitation, and post-TAVI complications....
Indication and device selection for tricuspid interventions
09 Feb 2025 – From PCR Tokyo Valves 2025
Want to sharpen your skills in selecting the right patients and devices for transcatheter tricuspid interventions? Don’t miss this session!
Learn how to assess anatomical suitability for T-TEER and TTVR, identify patients who may benefit from replacement over repair and explore the latest insights on timing and...
Lifetime management with self-expandable valve based on the latest evidence
09 Feb 2025 – From PCR Tokyo Valves 2025
Explore the latest evidence on the Evolut system and its impact on long-term valve durability in TAVR. Gain insights into its use for TAV-in-SAV procedures, the role of valve design in optimizing outcomes, and the importance of first-valve selection, commissure alignment, and coronary access.
How to optimise the patient outcomes - Key considerations for the small body population
08 Feb 2025 – From PCR Tokyo Valves 2025
Explore the latest strategies for optimizing outcomes in Asian and international patients with small body size. Through case presentations, surgical experiences, and the latest data on device performance, gain valuable insights into treating aortic stenosis more effectively. Discover how these advancements can enhance patient care and...
Late-Breaking Trial session
08 Feb 2025 – From PCR Tokyo Valves 2025
Discover the latest insights from pivotal studies in this PCR Tokyo Valves 2025 LBT session. Explore early feasibility updates from the AltaValve trial, in-hospital outcomes comparing surgical vs. percutaneous intervention in aortic stenosis with coronary artery disease from the JROAD-DPC data, and procedural results from the...
Transcatheter options for degenerated surgical aortic valves - LIVE case
Recommended by PCR
08 Feb 2025 – From PCR Tokyo Valves 2025
A 77-year-old male with a history of SAVR in 2011 (Magna Ease 23) and moderate chronic kidney disease, with preservedLV function, presented with symptomatic severe aortic regurgitation and stenosis, associated with severe MR.
A Sapien 3 Ultra Resilia 23 valve was implanted under local anesthesia, with hemodynamic...
Lifetime management
08 Feb 2025 – From PCR Tokyo Valves 2025
This PCR Tokyo Valves 2025 session explores the latest insights into TAVR explantation. It begins with the management of patients with longer life expectancy, then delves into surgical aortic valve replacement, aortic root enlargement, and commissural alignment—key techniques that may improve reintervention outcomes. The session also...
Nightmare in TAVI
08 Feb 2025 – From PCR Tokyo Valves 2025
Watch this session replay featuring two challenging cases: valve embolisation with a balloon-expandable valve and coronary obstruction with a self-expandable valve. Learn key lessons from the first case, including the importance of secure pacing, avoiding damage to the descending aorta while retrieving the embolised valve, and...
TAVI for pure aortic regurgitation - LIVE case
25 Nov 2024 – From PCR London Valves 2024
Watch a LIVE case followed by a recorded case on aortic regurgitation:
- An 86-year-old male with a history of stroke and prostate cancer presenting acute heart failure due to severe pure aortic regurgitation and LV dysfunction (EF 39%). A 27 mm JenaValve Trilogy prosthesis was implanted without...
Mind the gap! - What's missing in the field of transcatheter aortic valve interventions
25 Nov 2024 – From PCR London Valves 2024
This session aims to uncover the hidden gaps in the field of transcatheter aortic valve interventions (TAVI). Explore strategies for optimizing hemodynamics, durability, flow, and frame expansion post-TAVI. Review current knowledge and emerging approaches to improve hemodynamic performance, device durability, and flow dynamics after TAVI. Discuss...
Featured cases - Valve-in-valve TAVI with balloon fracture
24 Nov 2024 – From PCR London Valves 2024
Delve into the world of complex valve-in-valve TAVI procedures in this featured cases session. Explore a diverse range of challenging cases, including valve fracture techniques, managing unexpanded valves, and overcoming the Achilles' heel of valve-in-valve TAVI. Learn from the experiences of expert clinicians as they navigate...
Nightmares in TAVI: sharing solutions together
18 Feb 2024 – From PCR Tokyo Valves 2024
Consult this session to learn more about bailout techniques for TAVI during uncommon complications, such as late coronary obstruction post-TAVI, a migrated self-expandable valve, or a C-tab induced iatrogenic thoracic aortic dissection after Evolut FX implantation.
New devices for aortic intervention
18 Feb 2024 – From PCR Tokyo Valves 2024
In this session, discover a variety of abstract submissions concerning new devices for aortic intervention. Compare the clinical outcomes of the latest intra-annular devices, examine the differences in debris between SEV and PEV, and learn about PVL improvement after TAVI with a self-expanding valve.
Contemporary techniques for TAV-in-SAV interventions
18 Feb 2024 – From PCR Tokyo Valves 2024
Thanks to this session, take a look at the current outcomes of TAV-in-SAV, analyse the different types of valves and their fracturability, find out more, through case studies, about two different TAV-in-SAV techniques, with or without a stent, and learn how to avoid patient prosthesis mismatch...
Tricuspid and other structural interventions
18 Feb 2024 – From PCR Tokyo Valves 2024
In this series of submitted cases, explore challenges and bailouts around tricuspid valve intervention and other forms of structural interventions. Learn about a percutaneous solution to acute traumatic pulmonary regurgitation, a rare complication of inadequate sealing caused by anchor slip through the fabric part in a...
CAD and TAVI
18 Feb 2024 – From PCR Tokyo Valves 2024
What is the clinical impact of CAD in TAVR recipients and how best to treat it? Through this session, gain insight on how to determine optimal CAD assessment in TAVR recipients, learn the timing of coronary revascularisation pre-TAVR, and understand the exact assessment and treatment of...
TAVI for patients with concomitant coronary artery disease - LIVE case
17 Feb 2024 – From PCR Tokyo Valves 2024
An 88-year-old male presented a severe symptomatic aortic valve with preserved LV function (64%), a coronary artery disease with a LAD PCI a few years ago and a significant (75%) RCA stenosis with an FFR angio at 0.74. He also has a short membrane septum (2.5...
The optimal first valve choice for patients with aortic stenosis - Key considerations for lifetime management
17 Feb 2024 – From PCR Tokyo Valves 2024
This session tackles the pressing topic of TAVI's success in treating aortic stenosis, particularly in younger patients, and the ensuing questions regarding device durability, potential follow-up procedures, and the interplay between TAVI and surgical options. The aim is to ensure optimal decision-making that prioritizes patient welfare...
Mitral and tricuspid intervention
17 Feb 2024 – From PCR Tokyo Valves 2024
Consult this session to discover selected clinical cases regarding complex mitral and tricuspid interventions. Gain insights into phenotypes of secondary tricuspid regurgitation in echocardiography, learn about treatment effectiveness and one-year composite endpoint by clip size of TEER for AFMR, and more!